< Back to News

Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma

JANUARY 20, 2022  |  VIGEO THERAPEUTICS
https://vigeotherapeutics.com/news/vigeo-therapeutics-advances-vt1021-into-phase-2-3-registrational-study-for-glioblastoma/